Key result
Transcriptional profiling of right ventricles in iPAH and CTEPH patients identified early growth response 1 (EGR1) as a major profibrotic transcription factor in hypertrophic right ventricles.
Why the study?
Many pulmonary hypertension patients are deemed inoperable, and the underlying mechanisms governing right ventricular cardiac regeneration after surgical reverse remodeling remain largely elusive.
Does surgery for iPAH and CTEPH alter the transcriptional landscape of the right ventricle?
Observational
Does surgery for iPAH and CTEPH alter the transcriptional landscape of the right ventricle?
EGR1 is a major transcription factor implicated in right ventricular remodeling in pulmonary hypertension and may serve as a therapeutic target for inoperable patients.
RV performance monitoring in PH may guide clinical risk stratification; level 5 data leaves open causal remodeling mechanisms.
Background: Pulmonary hypertension (PH) is a vasoconstrictive disease characterized by elevated mean pulmonary arterial pressure (mPAP) at rest. Idiopathic pulmonary arterial hypertension (iPAH) and chronic thromboembolic pulmonary hypertension (CTEPH) represent two distinct subtypes of PH. Persisting PH leads to right ventricular (RV) hypertrophy, heart failure, and death. RV performance predicts survival and surgical interventions re-establishing physiological mPAP reverse cardiac remodeling. Nonetheless, a considerable number of PH patients are deemed inoperable. The underlying mechanism(s) governing cardiac regeneration, however, remain largely elusive. Methods: In a longitudinal approach, we profiled the transcriptional landscapes of hypertrophic RVs and recovered hearts 3 months after surgery of iPAH and CTEPH patients. Results: Genes associated with cellular responses to inflammatory stimuli and metal ions were downregulated, and cardiac muscle tissue development was induced in iPAH after recovery. In CTEPH patients, genes related to muscle cell development were decreased, and genes governing cardiac conduction were upregulated in RVs following regeneration. Intriguingly, early growth response 1 (EGR1), a profibrotic regulator, was identified as a major transcription factor of hypertrophic RVs in iPAH and CTEPH. A histological assessment confirmed our biocomputational results, and suggested a pivotal role for EGR1 in RV vasculopathy. Conclusion: Our findings improved our understanding of the molecular events driving reverse cardiac remodeling following surgery. EGR1 might represent a promising candidate for targeted therapy of PH patients not eligible for surgical treatment.
No takes yet. Share an insight, caveat, or question.
Laggner et al. (2022) conducted an observational in Idiopathic pulmonary arterial hypertension (iPAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Hypertrophic right ventricles before surgery vs. Recovered hearts 3 months after surgery was evaluated on Transcriptional landscape changes and EGR1 expression. Transcriptional profiling of right ventricles in iPAH and CTEPH patients identified early growth response 1 (EGR1) as a major profibrotic transcription factor in hypertrophic right ventricles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: